Modified Cotton Dressings for Treating Chronic Wounds

用于治疗慢性伤口的改良棉敷料

• 批准号: 6444874
• 负责人: IRWIN KELMAN COHEN
• 金额: $ 12.58万
• 依托单位: TISSUE TECHNOLOGIES HOLDING, LLC
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-04-12 至 2003-10-11
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6444874
• 关键词: cellulose; clinical research; cotton; decubitus ulcer; elastases; human subject; protease inhibitor; technology /technique development; wound; wound healing; wound infection

There is an immense need for developing clinically effective treatments of chronic wounds. Estimates of the costs for treating chronic wounds range into the billions of dollars annually. As Western society continues to age, the problem of chronic wounds will likely increase. Recent studies indicate proteases released during an over exuberant neutrophil response may have a significant role in the pathophysiology of chronic wounds. The objective of this proposed study is to test the feasibility of designing and developing dressings with the ability to sequestered/inhibit neutrophil derived proteases. Focus will be on the utilization of modified cellulosic-based materials. Cellulosic-based materials will be modified so as to introduce functional modalities that are predicted to bind neutrophil elastase and possibly other cationic neutrophil-derived proteases. In vitro assays will be used to assess the ability of several modified products to remove proteolytic activities from wound fluids. Candidate materials with desired sequestering properties will e further examined for pH stability, sterilization stability, and cytotoxicity. Besides their basis on a rational strategy, such a modified cellulosic-based material will have the additional advantage of being relatively inexpensive and thus have a high potential for use in the world-wide market. Once the principle has proved on a simple cellulosic dressing material, experiments will be conducted to expand the potential for other more sophisticated substrates for use as dressing materials (patents pending) and expanding the range of sequestering/inhibiting compounds onto the dressing or in the form of an ointment cream lotion. PROPOSED COMMERCIAL APPLICATIONS: The total cost for treating chronic wound sis estimated at $22-26 bn (Page 11), the cost of dressings used is in excess of $1 bn (Page 13). When compared with both currently available wound care products and those in development the technology has the following significant advantage: non invasive method of treatment; low cost of manufacture; potential to enter the 3rd world markets and bring affordable health care to this normally overlooked segment of the population; comparable clinical performance to the pharmaceutical growth factors that are priced at $300 per tube. This unique set of factors combine to offer a sales potential estimated at $95MM in the US and triple that number worldwide.

非常需要开发临床上有效的慢性伤口治疗方法。每年治疗慢性伤口的费用估计高达数十亿美元。随着西方社会不断老龄化，慢性伤口的问题可能会增加。最近的研究表明，中性粒细胞过度反应期间释放的蛋白酶可能在慢性伤口的病理生理学中发挥重要作用。这项研究的目的是测试设计和开发能够隔离/抑制中性粒细胞衍生蛋白酶的敷料的可行性。重点将放在改性纤维素基材料的利用上。基于纤维素的材料将被修改，以引入预计结合中性粒细胞弹性蛋白酶和可能的其他阳离子中性粒细胞衍生的蛋白酶的功能模式。体外测定将用于评估几种修饰产品去除伤口液中蛋白水解活性的能力。具有所需隔离特性的候选材料将进一步检查 pH 稳定性、灭菌稳定性和细胞毒性。除了基于合理策略之外，这种改性纤维素基材料还将具有相对便宜的额外优势，因此在全球市场上具有很高的使用潜力。一旦原理在简单的纤维素敷料材料上得到证实，将进行实验以扩大其他更复杂的基材用作敷料材料的潜力（正在申请专利），并扩大隔离/抑制化合物在敷料上或以形式的范围软膏霜乳液。拟议的商业应用：治疗慢性伤口的总成本估计为 22-26 亿美元（第 11 页），所用敷料的成本超过 10 亿美元（第 13 页）。与现有和正在开发的伤口护理产品相比，该技术具有以下显着优势：非侵入性治疗方法；制造成本低；进入第三世界市场并为这一通常被忽视的人群提供负担得起的医疗保健的潜力；临床性能与每管售价 300 美元的药物生长因子相当。这一系列独特的因素相结合，在美国的销售潜力估计为 95MM，在全球范围内是该数字的三倍。